Liao W - Search Results

1

Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer.

Yang Y, Feng M, Bai L, Liao W, Zhou K, Zhang M, Wu Q, Wen F, Lei W, Zhang P, Zhang N, Huang J, Li Q. Yang Y, et al. Among authors: liao w. J Transl Med. 2021 Sep 15;19(1):391. doi: 10.1186/s12967-021-03065-0. J Transl Med. 2021. PMID: 34526059 Free PMC article.

2

Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial.

Huang J, Liao W, Zhou J, Zhang P, Wen F, Wang X, Zhang M, Zhou K, Wu Q, Li Q. Huang J, et al. Among authors: liao w. Cancer Manag Res. 2018 Oct 1;10:4065-4072. doi: 10.2147/CMAR.S172704. eCollection 2018. Cancer Manag Res. 2018. PMID: 30323662 Free PMC article.

3

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.

Liao W, Huang J, Hutton D, Li Q. Liao W, et al. J Med Econ. 2019 Apr;22(4):344-349. doi: 10.1080/13696998.2019.1570221. Epub 2019 Feb 6. J Med Econ. 2019. PMID: 30646794 Free article.

4

Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.

Liao W, Huang J, Wu Q, Zhu G, Wang X, Wen F, Zhang P, Zhang N, Li Q. Liao W, et al. Oral Oncol. 2019 Jun;93:15-20. doi: 10.1016/j.oraloncology.2019.04.003. Epub 2019 Apr 9. Oral Oncol. 2019. PMID: 31109691

5

Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.

Liao W, Huang J, Hutton D, Zhu G, Wu Q, Wen F, Bai L, Li Q. Liao W, et al. Liver Int. 2019 Dec;39(12):2408-2416. doi: 10.1111/liv.14257. Epub 2019 Oct 3. Liver Int. 2019. PMID: 31544330 Free article.

6

S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.

Liao W, Huang J, Zhu G, Zhou J, Wen F, Zhang P, Zhou K, Wu Q, Wang X, Gou H, Li Q. Liao W, et al. Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):133-138. doi: 10.1080/14737167.2020.1677155. Epub 2019 Oct 10. Expert Rev Pharmacoecon Outcomes Res. 2020. PMID: 31597496 Clinical Trial.

7

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer.

Bai L, Zhang P, Zhou K, Liao W, Li Q. Bai L, et al. Among authors: liao w. Cancer Manag Res. 2019 Dec 12;11:10419-10426. doi: 10.2147/CMAR.S219318. eCollection 2019. Cancer Manag Res. 2019. PMID: 31849531 Free PMC article.

8

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.

Liao W, Huang J, Wu Q, Wen F, Zhang N, Zhou K, Bai L, Li Q. Liao W, et al. Breast Cancer. 2020 May;27(3):399-404. doi: 10.1007/s12282-019-01034-6. Epub 2019 Dec 18. Breast Cancer. 2020. PMID: 31853795

9

Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.

Wu Q, Liao W, Huang J, Zhang P, Zhang N, Li Q. Wu Q, et al. Among authors: liao w. Oral Oncol. 2020 Apr;103:104588. doi: 10.1016/j.oraloncology.2020.104588. Epub 2020 Feb 17. Oral Oncol. 2020. PMID: 32070923

10

Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.

Wu Q, Wang X, Zhang M, Liao W, Wang F, Li Q. Wu Q, et al. Among authors: liao w. Oncol Res Treat. 2020;43(4):153-159. doi: 10.1159/000505932. Epub 2020 Mar 18. Oncol Res Treat. 2020. PMID: 32187596

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,544 results

Search Page

Filters